» Articles » PMID: 22537538

Long-term Outcomes of Radiotherapy for Stage II Testicular Seminoma--the Mayo Clinic Experience

Overview
Journal Urol Oncol
Publisher Elsevier
Date 2012 Apr 28
PMID 22537538
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To report long-term outcomes of patients with stage II testicular seminoma treated with radiotherapy (RT).

Materials And Methods: A retrospective review was performed of 52 patients who received megavoltage RT for stage II testicular seminoma at Mayo Clinic between 1974 and 2007. Forty-eight patients (92%) had computed tomography staging. Overall survival (OS), relapse-free survival (RFS), and cause-specific survival (CSS) were determined using the Kaplan-Meier method. Major cardiac event (MCE) was defined as myocardial infarction, coronary artery bypass grafting or stenting, or valve replacement. Second malignancy (SM) was defined as biopsy-confirmed malignancy occurring in the RT field.

Results: The median patient age at diagnosis was 36 years. Stage was IIA (n = 24), IIB (n = 7), IIC (n = 17), and II not otherwise specified (NOS, n = 4). The median infradiaphragmatic RT dose was 30.7 Gy. Twenty-six patients (50%) received prophylactic mediastinal/supraclavicular (MSCV) RT. The median follow-up was 19 years. Estimates of OS, RFS, and CSS were 94%, 80%, and 96% at 10 years, and 83%, 72%, and 96% at 20 years, respectively. RFS at 10 years for stage IIA, IIB, IIC, and II NOS were 83%, 54%, 81%, and 100%, respectively (log-rank P = 0.21). Ten patients (19%) experienced disease relapse in the MSCV region (n = 7), para-aortic lymph nodes (n = 1), lung (n = 1), or peritoneal cavity (n = 1). Eight patients were successfully salvaged with chemotherapy and/or surgery, while 2 died of seminoma. Risk of MSCV relapse was significantly lower in patients who received MSCV RT vs. those who did not (10-year estimates: 4% vs. 21%, respectively, log-rank P = 0.01). MCE occurred in 10 patients (19%) at a median of 18 years (range 7-30) after RT. SM occurred in 5 patients (10%) at a median of 27 years (range 20-34) after RT.

Conclusions: In patients with stage II testicular seminoma treated with RT, relapse in the irradiated site was uncommon. Infradiaphragmatic RT alone was associated with a significant risk of MSCV failure. Most MCE and SM events occurred more than 20 years after RT, highlighting the importance of vigilant long-term follow-up.

Citing Articles

Contemporary surgical management of testicular seminoma.

Passarelli R, Pfail J, Jang T Transl Cancer Res. 2024; 13(11):6463-6472.

PMID: 39697723 PMC: 11651731. DOI: 10.21037/tcr-24-241.


Advances in radiation therapy for testicular seminoma.

Rosen D, Tan A, Pursley J, Kamran S World J Urol. 2023; 41(12):3895-3903.

PMID: 37979002 DOI: 10.1007/s00345-023-04674-8.


Therapy of clinical stage IIA and IIB seminoma: a systematic review.

Heinzelbecker J, Schmidt S, Lackner J, Busch J, Bokemeyer C, Classen J World J Urol. 2021; 40(12):2829-2841.

PMID: 34779882 PMC: 9712301. DOI: 10.1007/s00345-021-03873-5.


Contemporary management of early stage testicular seminoma.

Aydin A, Zemp L, Cheriyan S, Sexton W, Johnstone P Transl Androl Urol. 2020; 9(Suppl 1):S36-S44.

PMID: 32055484 PMC: 6995845. DOI: 10.21037/tau.2019.09.32.


Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach.

Lieng H, Warde P, Bedard P, Hamilton R, Hansen A, Jewett M Can Urol Assoc J. 2018; 12(2):59-66.

PMID: 29381453 PMC: 5937398. DOI: 10.5489/cuaj.4531.